Antimalarial Inhibitors that Target the Plasmodial Surface Anion Channel (PSAC) Protein and Development of the PSAC Protein as Vaccine Targets


There are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encoded by the clag3 gene. This discovery opens the possibility of developing the PSAC protein as a potential vaccine candidate against malaria.

Potential Commercial Applications: Competitive Advantages:
  • Antimalarial drugs
  • Malaria vaccine
 
  • Novel target against malaria
  • Small molecule inhibitors of PSAC inhibit malarial parasite growth, have low toxicity, and high specificity
  • PSAC protein is exposed on the surface of the infected host erythrocytes, making it an attractive vaccine candidate


Inventors:
Sanjay Desai (NIAID)


Intellectual Property:
US Application No. 61/474,583
PCT Application No. PCT/US12/33072
US Application No. 14/111,256


Publications:
Pillai AD, et al. PMID 22949525
Desai SA. PMID 22432505
Nguitragool W, et al. PMID 21620134
Pillai AD, et al. PMID 20101003

Licensing Contact:
Kevin Chang , Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325
Rockville , MD 20852
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220

OTT Reference No: E-145-2011/0

Updated: 04/23/2013